Vericel
Vericel Corp is an American advanced cell therapy biopharmaceutical company producing regenerative medicine products for sports medicine and severe burn care. The company manufactures and markets MACI, an autologous cellular scaffold for cartilage repair, alongside Epicel, a cultured epidermal autograft for severe burn treatment. Principal revenues stem from commercial sales of custom-manufactured cell therapy treatments directly to surgical health systems and specialized burn centers. Core end markets serve orthopedic surgeons, sports medicine clinics, reconstructive burn surgeons, and surgical hospitals across the United States. Vericel holds a market-leading position in advanced autologous cell therapy for cartilage repair and severe burn care in the US healthcare market. The corporation is headquartered in Cambridge, Massachusetts, and its common stock trades on the Nasdaq Global Select Market.
10 of the funds FundTelligence covers report a position in Vericel.
- Legal name
- Vericel Corp
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 10
Funds holding Vericel
- BNP Health Care Innovators — BNP Paribas · 1.8 % (full portfolio disclosed, June 2026)
- BNP US Small Cap — BNP Paribas · 1.44 % (full portfolio disclosed, June 2026)
- Nordea Global Small Cap — Nordea Funds · 1.38 % (full portfolio disclosed, September 2026)
- Nordea Global Small Cap Enhanced — Nordea Funds · 1.36 % (full portfolio disclosed, September 2026)
- Indecap Guide Global Offensiv — Indecap · 0.91 % (full portfolio disclosed, June 2026)
- Mercer Global Small Cap Equity Fund — Mercer · 0.23 % (full portfolio disclosed, December 2025)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.18 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.03 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 10 funds holding it.